First City Capital Management Inc. Purchases Shares of 5,224 GSK plc (NYSE:GSK)

First City Capital Management Inc. acquired a new stake in shares of GSK plc (NYSE:GSK) in the first quarter, Holdings Channel.com reports. The fund acquired 5,224 shares of the pharmaceutical company’s stock, valued at approximately $202,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Indiana Trust & Investment Management Co lifted its position in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after acquiring an additional 500 shares during the last quarter. Sierra Ocean LLC acquired a new stake in shares of GSK during the 4th quarter valued at $32,000. Parkside Financial Bank & Trust lifted its position in shares of GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock valued at $34,000 after acquiring an additional 818 shares during the last quarter. Golden State Wealth Management LLC acquired a new stake in shares of GSK during the 4th quarter valued at $38,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of GSK during the 4th quarter valued at $39,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

GSK opened at $41.22 on Friday. The stock has a fifty day moving average of $37.59 and a 200-day moving average of $36.39. The firm has a market capitalization of $85.05 billion, a P/E ratio of 25.92, a PEG ratio of 1.12 and a beta of 0.51. GSK plc has a 12-month low of $31.72 and a 12-month high of $44.67. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The business had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. During the same period last year, the company earned $0.43 earnings per share. GSK’s quarterly revenue was up 2.1% compared to the same quarter last year. Equities analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a dividend of $0.4216 per share. This represents a $1.69 annualized dividend and a dividend yield of 4.09%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. GSK’s dividend payout ratio (DPR) is currently 86.60%.

Analyst Ratings Changes

GSK has been the subject of a number of recent research reports. Hsbc Global Res upgraded GSK to a “strong sell” rating in a research report on Monday, April 28th. Morgan Stanley assumed coverage on GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. BNP Paribas assumed coverage on GSK in a report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 target price for the company. Berenberg Bank restated a “hold” rating on shares of GSK in a report on Tuesday. Finally, Wall Street Zen lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, May 30th. One analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK has an average rating of “Hold” and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.